Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Richard F. Little, MD

NCI - HIV and AIDS Malignancy Branch

Intervention

bevacizumab(biological)

Enrollment

15 target

Eligibility

18 years · All sexes

Timeline

2005 – 2007

Study locations (1)

• Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Primary effusion lymphoma

Additional recruiting or active studies for the same condition.

• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT02911142
  Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
  National Cancer Institute (NCI)

See all trials for Primary effusion lymphoma →